ANABAnaptysbio, Inc.
Anaptysbio, Inc. (ANAB) generates revenue through royalty streams tied to its partnered oncology therapies, including Jemperli and imsidolimab. The company’s next catalyst is the Jan 24, 2027 — Q3 2026 Earnings Release, which will test its ability to deliver consistent earnings guidance and progress on its royalty-generating partnerships.
- ANAB operates in a high-margin, asset-light model, leveraging its IP and partnerships to generate recurring revenue.
- The company has a history of meeting estimates but lacks near-term catalysts to drive upside.
- Its financials remain heavily leveraged, with a net loss of $115.03M in Q1 2026 and a free cash flow deficit of $166.07M over the last 12 months.
The Read
2% after Q1 2026 earnings met expectations without upside surprise.
The schedule
No upcoming catalysts on the current packet.
Past
- Mon3Aug
Actual outcome: Bull · $54.99 at outcome
AnaptysBio reported Q2 2026 EPS of -$1.84, meeting consensus estimates exactly. The stock exceeded the bull target as investors reacted positively to the company's successful transition into a focused royalty management company post-spin, which eliminated prior R&D burn and established a 95% targeted EBIT margin with over $140 million in net cash. Optimism surrounding escalating Jemperli royalties from GSK further drove the bullish price action.
First earnings print following recent spin-off activities, requiring updated full-year forward guidance and cash runway estimates.
- Tue12May
Actual outcome: Bear · $63.21 at outcome
AnaptysBio reported an EPS actual of -1.84, matching the estimate, but the stock fell 3.5% due to mixed guidance and uncertainty around partnership progress. The earnings beat was overshadowed by concerns over the company's ability to meet long-term revenue targets, leading to a bearish price reaction.
- Tue3Mar
Actual outcome: Bear · $39.80 at outcome
AnaptysBio reported Q4 2025 EPS of $1.79, exactly meeting consensus estimates, alongside updates on the GSK Jemperli milestone accrual. While the in-line earnings and milestone visibility drove a 13% relief rally, the stock's closing price of $39.80 failed to reclaim the $44.00 bear floor, resulting in a bear classification.